First, previous studies have reported that serum sclerostin levels are elevated in patients with osteolytic changes in multiple myeloma and bone metastases from breast cancer, and that the administration of anti-sclerostin antibody suppresses bone destruction in model mice [65,66,67,68,69]. This evidence concerns the gene SOST and plasma cell myeloma.